NYSE:BMY - Bristol-Myers Squibb Stock Price, Price Target & More

$51.61 -0.69 (-1.32 %)
(As of 04/20/2018 08:48 AM ET)
Previous Close$52.30
Today's Range$51.51 - $52.54
52-Week Range$51.51 - $70.05
Volume17.14 million shs
Average Volume8.57 million shs
Market Capitalization$85.38 billion
P/E Ratio17.15
Dividend Yield3.06%
Beta0.96

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb logoBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic development and commercialization collaboration agreement with Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:BMY
CUSIP11012210
Phone212-546-4000

Debt

Debt-to-Equity Ratio0.59%
Current Ratio1.55%
Quick Ratio1.43%

Price-To-Earnings

Trailing P/E Ratio17.15
Forward P/E Ratio16.03
P/E Growth1.41

Sales & Book Value

Annual Sales$20.78 billion
Price / Sales4.06
Cash Flow$3.4731 per share
Price / Cash14.86
Book Value$7.24 per share
Price / Book7.13

Profitability

EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Net Margins4.85%
Return on Equity35.43%
Return on Assets14.85%

Miscellaneous

Employees23,700
Outstanding Shares1,632,580,000

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, March 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) announced its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Zacks' consensus estimate of $0.67 by $0.01. The biopharmaceutical company earned $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY18 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of $3.15-3.30 for the period, compared to the Thomson Reuters consensus estimate of $3.23.

What price target have analysts set for BMY?

20 analysts have issued twelve-month target prices for Bristol-Myers Squibb's stock. Their predictions range from $47.00 to $78.00. On average, they expect Bristol-Myers Squibb's share price to reach $64.5269 in the next twelve months. View Analyst Ratings for Bristol-Myers Squibb.

What are Wall Street analysts saying about Bristol-Myers Squibb stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:
  • 1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up.  Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last three months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/29/2018)
  • 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)

Who are some of Bristol-Myers Squibb's key competitors?

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 53)
  • Mr. Charles A. Bancroft, CFO & Exec. VP of Global Bus. Operations (Age 58)
  • Dr. Thomas J. Lynch Jr., Exec. VP of R&D and Chief Scientific Officer (Age 57)
  • Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
  • Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)

Has Bristol-Myers Squibb been receiving favorable news coverage?

News headlines about BMY stock have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.09 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $51.61.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $85.38 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  722 (Vote Outperform)
Underperform Votes:  686 (Vote Underperform)
Total Votes:  1,408
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $64.5269, suggesting that the stock has a possible upside of 25.03%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.402.452.502.44
Ratings Breakdown: 1 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $64.5269$67.0894$65.2308$63.50
Price Target Upside: 25.03% upside0.99% upside4.50% upside1.06% downside

Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History

Price Target History for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018BMO Capital MarketsLower Price TargetUnderperform -> Underperform$51.00 -> $47.00LowView Rating Details
4/17/2018Credit Suisse GroupSet Price TargetHold$58.00LowView Rating Details
4/17/2018Bank of AmericaLower Price TargetNeutral -> Neutral$68.00 -> $61.00LowView Rating Details
4/17/2018William BlairReiterated RatingOutperformHighView Rating Details
4/17/2018Morgan StanleyDowngradeOverweight -> Equal Weight$54.08 -> $58.00HighView Rating Details
4/13/2018Jefferies GroupReiterated RatingHold$66.00LowView Rating Details
3/21/2018ArgusReiterated RatingBuy$75.00 -> $66.43LowView Rating Details
3/20/2018JPMorgan ChaseSet Price TargetOverweight -> Overweight$70.00 -> $75.00LowView Rating Details
2/28/2018DZ BankDowngradeBuy -> HoldHighView Rating Details
2/16/2018CitigroupSet Price TargetBuy$78.00LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetOutperform -> Positive$71.00 -> $76.00MediumView Rating Details
10/30/2017SunTrust BanksUpgradeHold -> BuyN/AView Rating Details
10/27/2017Piper JaffrayReiterated RatingHold$60.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$58.00 -> $65.00N/AView Rating Details
10/6/2017UBSReiterated RatingBuy$62.00 -> $72.00N/AView Rating Details
9/19/2017CowenReiterated RatingHold$65.00LowView Rating Details
9/12/2017Hilliard LyonsDowngradeLong-term Buy -> Neutral$65.00LowView Rating Details
9/7/2017Goldman SachsReiterated RatingBuy$62.00 -> $65.00LowView Rating Details
7/17/2017Deutsche BankSet Price TargetHold$54.00 -> $55.00LowView Rating Details
4/25/2017Robert W. BairdInitiated CoverageOutperformLowView Rating Details
2/9/2017GabelliReiterated RatingBuyN/AView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00N/AView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00N/AView Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Bristol-Myers Squibb (NYSE:BMY) Earnings History and Estimates Chart

Earnings by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Earnings Estimates

2018 EPS Consensus Estimate: $3.20
2019 EPS Consensus Estimate: $3.46
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.74$0.85$0.82
Q2 20183$0.76$0.82$0.80
Q3 20183$0.77$0.82$0.79
Q4 20183$0.76$0.84$0.80
Q1 20191$0.83$0.83$0.83
Q2 20191$0.85$0.85$0.85
Q3 20191$0.88$0.88$0.88
Q4 20191$0.90$0.90$0.90

Bristol-Myers Squibb (NYSE BMY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018$0.83N/AView Earnings Details
2/5/2018Q4 2017$0.67$0.68$5.3479 billion$5.4490 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.77$0.75$5.1957 billion$5.2540 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.73$0.74$5.0876 billion$5.1440 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.72$0.84$4.7485 billion$4.9290 billionViewN/AView Earnings Details
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.67$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.40$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bristol-Myers Squibb (NYSE:BMY) Dividend Information

Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.10%. BMY's next quarterly dividend payment will be made on Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.
Next Dividend:5/1/2018
Annual Dividend:$1.60
Dividend Yield:3.10%
Dividend Growth:2.70% (3 Year Average)
Payout Ratio:53.16% (Trailing 12 Months of Earnings)
49.69% (Based on This Year's Estimates)
42.78% (Based on Next Year's Estimates)
Track Record:8 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/1/2018quarterly$0.402.43568275232151%4/5/20184/6/20185/1/2018
12/7/2017quarterly$0.402.56%1/4/20181/5/20182/1/2018
9/13/2017quarterly$0.392.49%10/5/201710/6/201711/1/2017
6/13/2017quarterly$0.392.86%7/5/20177/7/20178/1/2017
3/2/2017quarterly$0.392.72%4/5/20174/7/20175/1/2017
12/8/2016quarterly$0.392.73%1/4/20171/6/20172/1/2017
8/3/2016quarterly$0.382.02%10/5/201610/7/201611/1/2016
6/7/2016quarterly$0.382.07%6/29/20167/1/20168/1/2016
3/3/2016quarterly$0.382.35%3/30/20164/1/20165/2/2016
12/8/2015quarterly$0.382.22%12/30/20151/4/20162/1/2016
9/17/2015quarterly$0.372.3%9/30/201510/2/201511/2/2015
6/16/2015quarterly$0.372.23%7/1/20157/6/20158/3/2015
3/2/2015quarterly$0.372.39%4/1/20154/6/20155/1/2015
12/9/2014quarterly$0.372.5%12/30/20141/2/20152/2/2015
9/16/2014quarterly$0.362.83%10/1/201410/3/201411/3/2014
6/17/2014quarterly$0.363%7/1/20147/3/20148/1/2014
3/3/2014quarterly$0.362.55%4/2/20144/4/20145/1/2014
12/19/2013quarterly$0.362.7%12/31/20131/3/20142/3/2014
9/17/2013quarterly$0.352.95%10/2/201310/4/201311/1/2013
6/19/2013quarterly$0.353.14%7/2/20137/5/20138/1/2013
3/7/2013quarterly$0.353.74%4/3/20134/5/20135/1/2013
12/4/2012quarterly$0.351/4/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 71.51%
Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)
Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE BMY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Theodore R Samuels IIDirectorBuy4,000$62.30$249,200.0022,000View SEC Filing  
12/12/2017Thomas J Jr. LynchEVPSell5,300$63.24$335,172.009,251View SEC Filing  
12/4/2017Sandra LeungEVPSell156,582$63.37$9,922,601.34584,373View SEC Filing  
9/6/2017Joseph C CaldarellaSVPSell9,340$60.00$560,400.0046,297View SEC Filing  
8/2/2017Theodore R Samuels IIDirectorBuy6,000$55.94$335,640.0018,000View SEC Filing  
4/7/2017Lamberto AndreottiDirectorSell34,000$53.26$1,810,840.00952,571View SEC Filing  
3/28/2017Lamberto AndreottiDirectorSell34,000$56.17$1,909,780.00986,112View SEC Filing  
3/27/2017Lamberto AndreottiDirectorSell17,000$56.14$954,380.00986,112View SEC Filing  
3/17/2017Louis S SchmuklerInsiderSell5,000$56.49$282,450.0021,483View SEC Filing  
3/15/2017Joseph C CaldarellaSVPSell8,096$57.29$463,819.8455,637View SEC Filing  
3/6/2017Sandra LeungEVPSell92,405$57.02$5,268,933.10488,063View SEC Filing  
2/27/2017Theodore R Samuels IIDirectorBuy12,000$56.77$681,240.0012,000View SEC Filing  
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00334,499View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00364,999View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00380,099View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00403,094View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.8055,011View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79184,694View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.9355,238View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16444,507View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00425,194View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14132,263View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94128,463View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60536,794View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.1021,971View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00453,094View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00453,094View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00381,254View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.002,500View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.6846,322View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.2076,738View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64309,547View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00392,854View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00310,424View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00310,424View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00332,852View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00456,052View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00524,252View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00546,874View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.4068,965View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00630,783View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.198,861View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00273,393View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.1214,696View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.7249,753View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.4832,740View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00207,237View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.0577,303View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20195,855View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50500,487View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.9059,355View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00373,393View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines

Source:
DateHeadline
Bristol-Myers' Opdivo Gets Priority Review for Lung CancerBristol-Myers' Opdivo Gets Priority Review for Lung Cancer
finance.yahoo.com - April 20 at 8:41 AM
Bristol-Myers Opdivo Gets Priority Review for Lung CancerBristol-Myers' Opdivo Gets Priority Review for Lung Cancer
www.zacks.com - April 19 at 5:23 PM
Bristol-Myers Squibb (BMY) PT Set at $65.00 by CowenBristol-Myers Squibb (BMY) PT Set at $65.00 by Cowen
www.americanbankingnews.com - April 19 at 12:16 PM
Bristol-Myers Squibb (BMY) Says FDA Accepted sBLA for Opdivo in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority ReviewBristol-Myers Squibb (BMY) Says FDA Accepted sBLA for Opdivo in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
www.streetinsider.com - April 19 at 8:54 AM
Im Buying Bristol-Myers Down Near 52-Week LowsI'm Buying Bristol-Myers Down Near 52-Week Lows
seekingalpha.com - April 19 at 8:54 AM
Cabometyx Could Be Exelixis’s Long-Term Growth DriverCabometyx Could Be Exelixis’s Long-Term Growth Driver
finance.yahoo.com - April 19 at 8:54 AM
Bristol-Myers Squibb (BMY) Scheduled to Post Earnings on ThursdayBristol-Myers Squibb (BMY) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:56 AM
Bristol-Myers Squibb (BMY) Given Average Rating of "Hold" by BrokeragesBristol-Myers Squibb (BMY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 5:30 PM
Bristol-Myers Squibb (BMY) Rating Increased to Strong-Buy at VetrBristol-Myers Squibb (BMY) Rating Increased to Strong-Buy at Vetr
www.americanbankingnews.com - April 18 at 5:18 PM
FDA OKs Bristol-Myers Opdivo + Yervoy for first-line kidney cancerFDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer
seekingalpha.com - April 18 at 5:10 PM
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority ReviewU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
finance.yahoo.com - April 18 at 5:10 PM
Trader adding to this beaten pharma stockTrader adding to this beaten pharma stock
finance.yahoo.com - April 18 at 5:10 PM
Bristol-Myers Squibb (BMY) Price Target Lowered to $47.00 at BMO Capital MarketsBristol-Myers Squibb (BMY) Price Target Lowered to $47.00 at BMO Capital Markets
www.americanbankingnews.com - April 18 at 10:38 AM
Bristol-Myers Squibb (BMY) Given a $58.00 Price Target by Credit Suisse Group AnalystsBristol-Myers Squibb (BMY) Given a $58.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - April 18 at 8:41 AM
FY2018 Earnings Forecast for Bristol-Myers Squibb (BMY) Issued By William BlairFY2018 Earnings Forecast for Bristol-Myers Squibb (BMY) Issued By William Blair
www.americanbankingnews.com - April 18 at 8:38 AM
Q1 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By SunTrust BanksQ1 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By SunTrust Banks
www.americanbankingnews.com - April 18 at 7:58 AM
Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY)Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY)
finance.yahoo.com - April 17 at 5:21 PM
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares BetterBristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
www.msn.com - April 17 at 5:21 PM
Bristol-Myers Squibb (BMY) Price Target Lowered to $61.00 at Bank of AmericaBristol-Myers Squibb (BMY) Price Target Lowered to $61.00 at Bank of America
www.americanbankingnews.com - April 17 at 3:03 PM
Bristol-Myers Squibb (BMY) Rating Reiterated by William BlairBristol-Myers Squibb (BMY) Rating Reiterated by William Blair
www.americanbankingnews.com - April 17 at 9:19 AM
BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa InhibitorsBRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors
www.reuters.com - April 17 at 8:37 AM
Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right oneWhy Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one
www.businessinsider.com - April 17 at 8:37 AM
Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition TargetsPfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets
www.msn.com - April 17 at 8:37 AM
Morgan Stanley Downgrades Bristol-Myers Squibb (BMY) to HoldMorgan Stanley Downgrades Bristol-Myers Squibb (BMY) to Hold
www.americanbankingnews.com - April 17 at 8:11 AM
$5.10 Billion in Sales Expected for Bristol-Myers Squibb (BMY) This Quarter$5.10 Billion in Sales Expected for Bristol-Myers Squibb (BMY) This Quarter
www.americanbankingnews.com - April 17 at 4:59 AM
Bristol-Myers teams up with J&J to develop next-gen cardiovascular therapyBristol-Myers teams up with J&J to develop next-gen cardiovascular therapy
seekingalpha.com - April 16 at 5:20 PM
Bristol-Myers Reports Positive Data in NSCLC Trial on OpdivoBristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
www.msn.com - April 16 at 5:20 PM
BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 PctBRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct
www.reuters.com - April 16 at 5:20 PM
Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular TherapyBristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
finance.yahoo.com - April 16 at 5:20 PM
Merck Cements Lead in Lung Cancer With Bristol-Myers FizzlingMerck Cements Lead in Lung Cancer With Bristol-Myers Fizzling
www.msn.com - April 16 at 5:20 PM
Bristol-Myers Partners With Janssen on Anticlotting TherapyBristol-Myers Partners With Janssen on Anticlotting Therapy
www.bloomberg.com - April 16 at 5:20 PM
Global Antidiabetics Market Overview 2017-2026: Eli Lilly, Abbott Laboratories, Bristol-Myers SquibbGlobal Antidiabetics Market Overview 2017-2026: Eli Lilly, Abbott Laboratories, Bristol-Myers Squibb
www.marketwatch.com - April 16 at 9:17 AM
Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)
finance.yahoo.com - April 16 at 9:17 AM
Bristol-Myers Squibb to Post Q1 2018 Earnings of $0.85 Per Share, Jefferies Group Forecasts (BMY)Bristol-Myers Squibb to Post Q1 2018 Earnings of $0.85 Per Share, Jefferies Group Forecasts (BMY)
www.americanbankingnews.com - April 16 at 1:44 AM
Bristol-Myers Squibb (BMY) Raised to Strong-Buy at VetrBristol-Myers Squibb (BMY) Raised to Strong-Buy at Vetr
www.americanbankingnews.com - April 15 at 8:22 PM
Zacks: Brokerages Expect Bristol-Myers Squibb (BMY) Will Post Earnings of $0.84 Per ShareZacks: Brokerages Expect Bristol-Myers Squibb (BMY) Will Post Earnings of $0.84 Per Share
www.americanbankingnews.com - April 15 at 3:11 AM
Bristol-Myers Squibb (BMY) Rating Lowered to Sell at BidaskClubBristol-Myers Squibb (BMY) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:05 AM
Bristol-Myers teams up with Illumina to develop companion diagnostics for cancer immunotherapiesBristol-Myers teams up with Illumina to develop companion diagnostics for cancer immunotherapies
seekingalpha.com - April 13 at 5:18 PM
BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibbs Oncology ImmunotherapiesBRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies
www.reuters.com - April 13 at 5:18 PM
Bristol-Myers Opdivo extends survival in late-stage lung study in Chinese populationBristol-Myers' Opdivo extends survival in late-stage lung study in Chinese population
seekingalpha.com - April 13 at 5:18 PM
Bristol-Myers Collaborates With Harvard Fibrosis NetworkBristol-Myers Collaborates With Harvard Fibrosis Network
finance.yahoo.com - April 13 at 5:18 PM
Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC)Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - April 13 at 5:18 PM
Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology ImmunotherapiesBristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies
finance.yahoo.com - April 13 at 5:18 PM
Illumina shares advance on Bristol-Myers cancer drug collaborationIllumina shares advance on Bristol-Myers cancer drug collaboration
finance.yahoo.com - April 13 at 5:18 PM
Bristol-Myers Squibb (BMY) Given a $66.00 Price Target at Jefferies GroupBristol-Myers Squibb (BMY) Given a $66.00 Price Target at Jefferies Group
www.americanbankingnews.com - April 13 at 10:13 AM
Global Acute lymphocytic/lymphoblastic leukemia therapeutics Market Overview 2017-2026: Amgen, Bristol- Myers SquibbGlobal Acute lymphocytic/lymphoblastic leukemia therapeutics Market Overview 2017-2026: Amgen, Bristol- Myers Squibb
www.marketwatch.com - April 13 at 8:46 AM
Global Antidiabetic Sulphonylureas Market Overview 2017-2026: Novo Nordisk, Bristol-Myers SquibbGlobal Antidiabetic Sulphonylureas Market Overview 2017-2026: Novo Nordisk, Bristol-Myers Squibb
www.marketwatch.com - April 13 at 8:46 AM
Around Town Nat: Pressley Ridge, MDA, Carlow University and Bristol-Myers SquibbAround Town N'at: Pressley Ridge, MDA, Carlow University and Bristol-Myers Squibb
www.bizjournals.com - April 13 at 8:46 AM
Drugmakers vie for dominance in lung cancer treatmentDrugmakers vie for dominance in lung cancer treatment
finance.yahoo.com - April 13 at 8:46 AM
Pfizers Deal Potential Doesnt Stop at Bristol-MyersPfizer's Deal Potential Doesn't Stop at Bristol-Myers
www.bloomberg.com - April 12 at 5:19 PM

SEC Filings

Bristol-Myers Squibb (NYSE:BMY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bristol-Myers Squibb (NYSE BMY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.